Halozyme Therapeutics Inc HALO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HALO is a good fit for your portfolio.
News
-
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
-
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
-
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
-
Halozyme to Participate in Upcoming Investor Conferences
-
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
-
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation
-
Mahesh Krishnan Elected to Halozyme's Board of Directors
Trading Information
- Previous Close Price
- $50.83
- Day Range
- $49.30–51.67
- 52-Week Range
- $32.79–52.73
- Bid/Ask
- $51.36 / $51.45
- Market Cap
- $6.55 Bil
- Volume/Avg
- 1.2 Mil / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 20.84
- Price/Sales
- 7.77
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 3.90%
Company Profile
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 373
- Website
- https://www.halozyme.com
Comparables
Valuation
|
Metric
|
HALO
|
ABVX
|
MRNA
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.84 | — | 56.21 |
Price/Book Value | 36.37 | 4.14 | 4.51 |
Price/Sales | 7.77 | — | 11.32 |
Price/Cash Flow | 14.52 | — | — |
Price/Earnings
HALO
ABVX
MRNA
Financial Strength
|
Metric
|
HALO
|
ABVX
|
MRNA
|
|---|---|---|---|
Quick Ratio | 5.07 | 4.00 | 3.74 |
Current Ratio | 6.64 | 4.08 | 4.03 |
Interest Coverage | 19.57 | −9.89 | −148.54 |
Quick Ratio
HALO
ABVX
MRNA
Profitability
|
Metric
|
HALO
|
ABVX
|
MRNA
|
|---|---|---|---|
Return on Assets (Normalized) | 18.90% | −70.24% | −20.12% |
Return on Equity (Normalized) | 233.20% | −142.04% | −26.85% |
Return on Invested Capital (Normalized) | 21.58% | −89.54% | −26.68% |
Return on Assets
HALO
ABVX
MRNA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Gtscnxch | Twmf | $639.9 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tlvntdbq | Sqbfh | $124.7 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gzyykyft | Xmttmhh | $110.5 Bil | |||
| Moderna Inc
MRNA
| Mxjllkjj | Btbtp | $57.9 Bil | |||
| BioNTech SE ADR
BNTX
| Whyswsyk | Xdxg | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Pnjfpmyx | Mpt | $22.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pqqkqdr | Jrltrxt | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wgwwdbc | Rgpsqp | $15.3 Bil | |||
| Incyte Corp
INCY
| Zgdxmwfd | Jnkyqy | $13.3 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Gsnrdwxlm | Hggzyr | $12.4 Bil |